Unknown

Dataset Information

0

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.


ABSTRACT: This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300 mg orally on days 1-21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21 h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients.

SUBMITTER: Verstovsek S 

PROVIDER: S-EPMC4414320 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications


This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300 mg orally on days 1-21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppres  ...[more]

Similar Datasets

| S-EPMC5344293 | biostudies-literature
| S-EPMC8504815 | biostudies-literature
| S-EPMC4007851 | biostudies-literature
| S-EPMC6288363 | biostudies-literature
| S-EPMC5927969 | biostudies-literature
| S-EPMC3255248 | biostudies-literature
| S-EPMC4558588 | biostudies-literature
| S-EPMC8170698 | biostudies-literature
| S-EPMC10894844 | biostudies-literature